Belbuca vs Suboxone: Same Drug, Different Job

What is the difference between Belbuca and Suboxone?

Both are buprenorphine. Both dissolve in the mouth. Both are Schedule III.

They are not interchangeable. Belbuca is a pain medicine. Suboxone treats opioid use disorder. The doses are a different order of magnitude, and one of them has naloxone in it.

So the useful question is not which is stronger. It is which job the prescription is for.

Everything in the table comes from the FDA labels for Belbuca and Suboxone, except the prescriber row for Suboxone, which reflects the 2023 end of the federal X-waiver; see SAMHSA.

Micrograms vs milligrams: the number that matters

Belbuca strengths are in micrograms. Suboxone strengths are in milligrams. A milligram is a thousand micrograms.

Belbuca’s highest allowed dose, 900 mcg every 12 hours, adds up to 1.8 mg of buprenorphine a day. The Suboxone label’s maintenance range starts at 4 mg a day and names 16 mg as the recommended dose once induction is done. On paper, Belbuca’s ceiling is less than half the bottom of that range and about a ninth of the 16 mg dose. That compares labeled amounts only: a cheek film and a film under the tongue are absorbed differently, so the numbers are not a measure of strength or a conversion chart.

That gap is the whole story for most readers. Someone stable on Suboxone for opioid use disorder cannot swap to Belbuca and expect the same effect, and someone on Belbuca for pain is not “on Suboxone.”

Is Belbuca used for opioid addiction?

Not by its label. Belbuca is FDA-approved only for pain. Its label does mention opioid use disorder, including as a risk factor for overdose that should prompt access to naloxone, and in telling prescribers that when Belbuca is stopped because of a suspected substance use disorder, they should evaluate and treat it or refer, with evidence-based approaches such as medication treatment of opioid use disorder.

The products approved for opioid use disorder are the sublingual buprenorphine films and tablets (Suboxone, its generics, generic buprenorphine tablets, Zubsolv) and the long-acting injections (Sublocade, Brixadi). Our Suboxone vs Subutex vs Sublocade guide compares them.

Can you be on Belbuca and Suboxone at the same time?

That is a question for the prescribers, plural, and both of them need to know about the other prescription. Two buprenorphine prescriptions from two prescribers who do not know about each other can add up to more than either one intended. If pain is part of the picture for someone in treatment for opioid use disorder, the prescriber managing the Suboxone is the right first call.

Switching from another opioid to Belbuca: the withdrawal warning

Buprenorphine binds tightly and gives a weaker signal than full opioids. Started on top of a full opioid, it can push that opioid off the receptors and cause precipitated withdrawal. The Belbuca label says this directly: to reduce the risk, patients should be tapered to no more than 30 mg of oral morphine equivalents a day before starting. For people on more than 160 mg a day, the label says to consider a different pain medicine.

Suboxone’s label handles the same problem from the other side. Its first dose is given once a person is in withdrawal, and for people dependent on methadone or other long-acting opioids, the label recommends starting on buprenorphine alone on days 1 and 2. Either way, the rule is the same: buprenorphine on top of a full opioid is a withdrawal waiting to happen, so the switch is planned with a prescriber, never improvised.

Side effects they share

• Teeth. Both labels warn of dental problems with buprenorphine that dissolves in the mouth, including cavities, abscesses, and tooth loss. Both say to rinse with water after the film dissolves and wait at least an hour before brushing.
• Breathing. Both warn about respiratory depression, most of all with alcohol, benzodiazepines, or other sedatives.
• Liver. The Belbuca label repeats the liver warnings seen with sublingual buprenorphine for opioid dependence.
• Heart rhythm. Belbuca’s dose ceiling exists because of QT prolongation.
• Stopping. The Belbuca label says not to stop suddenly in someone physically dependent; rapid reduction has led to serious withdrawal, uncontrolled pain, and suicide. Taper with the prescriber.

Subutex 8 mg: what it is now

Subutex was the brand name for buprenorphine without naloxone, as a tablet under the tongue. The brand is listed as discontinued in FDA records, with an FDA finding that it was not withdrawn for safety or effectiveness reasons. Generic buprenorphine sublingual tablets come in 2 mg and 8 mg.

The generic tablet label says it treats opioid dependence and is preferred for induction, the first days of treatment. An 8 mg tablet is a typical building block: in one study on the label, patients took 8 mg on day 1 and 16 mg on day 2. Imprints differ by manufacturer, so a pharmacist or the label for that specific product is the way to confirm a pill. A buprenorphine tablet from anywhere but a pharmacy cannot be trusted to be buprenorphine.

8 mg of Subutex and an 8/2 mg Suboxone film carry the same amount of buprenorphine. The difference is the naloxone. Our Suboxone vs Subutex guide explains why naloxone is there and who gets buprenorphine without it.

Sublocade (often searched as “sublicade”)

Sublocade is buprenorphine in a monthly injection under the skin, for moderate to severe opioid use disorder. Its label says:

• It is given only by a health care provider, in the abdomen, thigh, buttock, or back of the upper arm, and only through a restricted REMS program; it is not available in retail pharmacies
• People not already on buprenorphine get a first dose (for example, 4 mg) of buprenorphine under the tongue or in the cheek before the first injection
• The usual schedule is two monthly 300 mg doses, then 100 mg monthly; the second injection can come as early as one week after the first
• Injecting it into a vein can cause serious harm or death, because it turns solid in the body

Belbuca and Sublocade have nothing in common but the molecule. One is a twice-daily film for pain. The other is a monthly shot for addiction treatment.

Butrans: the other pain buprenorphine

Butrans-type buprenorphine patches are the third pain form. The patch label carries the same pain indication as Belbuca, is worn for 7 days at a time, and comes in strengths measured in micrograms per hour, starting at 5. Like Belbuca, it is a pain product and not approved for opioid use disorder.

Why the difference matters for detox

Someone on Belbuca for months is physically dependent on an opioid, even when it is taken exactly as prescribed. That is not the same as addiction, and stopping it is a taper planned with the prescriber, not a detox admission. When use has gone beyond the prescription, or other opioids are involved, the picture changes, and so does the medication: treatment for opioid use disorder uses the products approved for it, at the doses approved for it.

Those medications keep people alive. Pooled cohort studies in the BMJ (Sordo, 2017) and JAMA Psychiatry (Santo, 2021) found all-cause death rates about half as high or lower during time on methadone or buprenorphine than during time off them. Sordo also found sharply higher death rates right after people leave treatment, so stopping is never a casual decision.

Our opioid detox guide covers where to go in New Jersey, and the medication treatment guide compares buprenorphine, methadone, and naltrexone.

In New Jersey

Under New Jersey law P.L.2017, c.28, fully insured New Jersey plans and the State Health Benefits and School Employees’ plans cannot require prior authorization for the first 180 days per plan year of in-network treatment your own physician, psychologist or psychiatrist finds medically necessary, or, during those same 180 days, for outpatient prescription drugs that treat substance use disorder, such as buprenorphine and naltrexone, when that clinician finds them medically necessary. Self-funded employer plans, Medicare and Medicaid are not covered by that rule, so verify with the plan. That rule is written for drugs that treat substance use disorder, so do not assume it applies to Belbuca prescribed for pain; ask the plan how it handles that prescription. NJ FamilyCare covers buprenorphine, methadone, and naltrexone. Our insurance guides go plan by plan.

For help independent of us, the state’s IME Addictions Access Center at 1-844-276-2777 screens NJ FamilyCare and uninsured residents and refers them to treatment, and ReachNJ, the state treatment line, is at 1-844-732-2465. Periscope Behavioral Health, which publishes this site, is opening a medical detox in Hammonton, Atlantic County, expected Summer 2027. Until it opens, Periscope Behavioral Health at (888) 313-3583, our publisher’s admissions line, can talk through options in New Jersey and Florida, including facilities Periscope operates. What a plan covers depends on the plan and the facility’s network status.

Which one are you actually asking about?

Same molecule, four different conversations. Start the right one.